BMJ Sexual & Reproductive Health, Год журнала: 2024, Номер unknown, С. bmjsrh - 202427
Опубликована: Окт. 9, 2024
Язык: Английский
Andrology, Год журнала: 2024, Номер 12(7), С. 1506 - 1511
Опубликована: Май 15, 2024
Abstract Background Current options for male contraception are limited to condoms, the withdrawal method, or a vasectomy. Studies indicate that men have expressed growing interest in bearing responsibility family planning. Objectives To review prior studies investigating role of an androgen‐only androgen with progestin regimen hormonal and provide update promising new agent, transdermal gel. Discussion Thus far, there been six conducted couples evaluating contraceptive efficacy co‐administered contraception. The only ongoing study is by National Institute Child Health Human Development, collaboration Population Council. They developed novel gel containing testosterone segesterone acetate (Nestorone), progestin. An phase II enrolling more than 460 has shown great potential respect product's efficacy, safety, reversibility, acceptability. As this agent advances development, rapid at‐home test sperm concentration will immediate feedback regarding their pregnancy. Conclusion There promise first‐of‐its‐kind contraceptive, gel, achieve market approval distribution United States elsewhere. Its user‐control all appealing qualities make it readily adoptable clinical practice.
Язык: Английский
Процитировано
6
Andrology, Год журнала: 2024, Номер 12(7), С. 1541 - 1546
Опубликована: Май 22, 2024
Abstract Vasectomy is the most commonly performed urologic procedure in United States and a highly effective form of male contraception. The introduction guidelines by urological societies has standardized vasectomy care. Providers should be awadre rationale behind these guidelines, as well key differences among them. While few major changes to technique have been adopted over past 40 years, new, reversible vasal occlusive technologies may affect delivery contraceptive care future. Here, we perform comparative review from six worldwide. In addition, report on status several experimental occlusion methods that available next decade.
Язык: Английский
Процитировано
3
Contraception, Год журнала: 2025, Номер unknown, С. 110830 - 110830
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
International Journal of Impotence Research, Год журнала: 2025, Номер unknown
Опубликована: Март 29, 2025
Язык: Английский
Процитировано
0
Andrology, Год журнала: 2025, Номер unknown
Опубликована: Апрель 8, 2025
Abstract Background Standardized methodology for reporting outcomes male contraceptive trials has not been published. For studies that suppress spermatogenesis, failures can occur during the sperm suppression phase or by rebound due to an unintended pregnancy efficacy phase. These three types of failure differ from female contraceptives and necessitate a novel approach results trials. Methods A standardized is proposed highlighting failure: failure, rebound, pregnancy. This used retrospectively analyze published studies. Data on adverse events other dropouts these data condom use are also presented give overall picture effectiveness methods. Results In 2217 men enrolled in five hormonal included analysis, rate was 3.3% (95% CI: 2.6–4.2). The 1.4% 0.9%–1.9%), 1.1% 0.8%–1.7%). combined 6.2% 5.2%–7.3%). trials, occurred 3.9% 3.1%–4.9%) men, while discontinuations reasons 20% 18%–22%) men. total, 70% 68%–72%) experienced effective contraception. Conclusions Contraceptive may be described with three‐outcome approach. Combining measures event dropout rates clearer understanding method under study.
Язык: Английский
Процитировано
0
Andrology, Год журнала: 2024, Номер 12(7), С. 1574 - 1584
Опубликована: Июль 19, 2024
Abstract Introdction Human spermatogenesis is a complex process that transforms spermatogonial stem cells through mitosis and meiosis to spermatozoa. Testosterone the key regulator of terminal stages meiosis, adherence spermatids Sertoli cells, spermiation. Follicle‐stimulating hormone (FSH) may be required for early important maintaining normal in men. Hormonal contraception suppresses FSH, luteinizing hormone, intratesticular testosterone concentration, resulting marked suppression sperm output. Results Clinical trials using alone or plus progestin demonstrate sustained concentration ≤1 million/mL sufficient prevent pregnancy female partner. New agents target could use this as contraceptive efficacy while others block function transport require lower threshold. When concentrations are suppressed such low levels, measurement motility morphology technically difficult unnecessary. With current data from fertile infertile men, it not possible establish limit percent equates prevention conception. compounds decrease alter need complete absence altered all spermatozoa ejaculate. Sperm tests useful depending on mechanism action each new compound. Conclusion Monitoring surrogate markers ensure effective relies laboratories experienced semen analyses. The development at‐home assess parameters has progressed rapidly. Some have been assessed clinical approved by regulatory agencies fertility assessment. However, caution must exercised these many rigorously validated against measured trained technologists standardized defined World Health Organization Semen Manual.
Язык: Английский
Процитировано
2
Andrology, Год журнала: 2024, Номер 12(7), С. 1535 - 1540
Опубликована: Июль 29, 2024
Male contraception includes various methods designed to prevent pregnancy by focusing on the male's role in reproduction.
Язык: Английский
Процитировано
2
Andrology, Год журнала: 2024, Номер 12(7), С. 1590 - 1599
Опубликована: Авг. 2, 2024
Abstract Introduction Progress in male contraception development faces the challenge of a lack regulatory precedent and guidelines on evidence (trial design primary endpoint) required for marketing approval. Moreover, contraceptive is complicated by fact that clinical treatment effect; prevention pregnancy, not measured patient receiving intervention. Discussion Regulatory exist female hormonal contraceptives but their applicability to products likely varies based mode action anticipated pharmacodynamic effects product. The unique attributes contraceptives, including frequent delay between intervention (e.g., vasectomy methods) ultimate effect, sperm suppression near azoospermia, pregnancy need be addressed. Conclusion This article describes challenges faced developers offers proposals, paving way both methods non‐hormonal approaches. Our intends suggest directions cannot substitute advice agencies.
Язык: Английский
Процитировано
2
Andrology, Год журнала: 2024, Номер 12(7), С. 1529 - 1534
Опубликована: Июль 29, 2024
Abstract Non‐surgical (reversible) male contraception methods, when approved for general clinical application, should be made available to all interested men aged 18 50 years in good health regardless of their semen parameters. In the preliminary workup, a complete personal and family history aimed at identifying specific conditions that may potentially increase risks adverse effects (associated with testosterone replacement) is advisable but or andrological examination not required, unless indicated by history. Baseline body weight, blood pressure haemoglobin recorded purpose future monitoring. While benefits vasectomy have been well established, appropriately nuanced patient counselling assessment are essential ensuring satisfactory outcome vasectomy.
Язык: Английский
Процитировано
1
Andrology, Год журнала: 2024, Номер 12(7), С. 1558 - 1567
Опубликована: Июль 30, 2024
This manuscript presents non-hormonal male contraceptive development in the context of mitigating risk to investigators and investors.
Язык: Английский
Процитировано
1